ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Virus Like Particles Market Research Report 2025
Published Date: August 2025
|
Report Code: QYRE-Auto-8E9893
Home | Market Reports | Health| Pharmacy
Global Virus Like Particles Market Insights and Forecast to 2028
BUY CHAPTERS

Global Virus Like Particles Market Research Report 2025

Code: QYRE-Auto-8E9893
Report
August 2025
Pages:89
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
GlaxoSmithKline PLC
Merck
Novavax Inc
Takeda
Medicago
MedImmune
TechnoVax
Agilvax
Allergy Therapeutics
Serum Institute of India
GeoVax Labs
Cytos Biotechnology
ANGANY Genetics
CPL Biologicals
Xiamen Innovax Biotech

Virus Like Particles Market

The global market for Virus Like Particles was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
North American market for Virus Like Particles is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Virus Like Particles is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Virus Like Particles include GlaxoSmithKline, Merck, Novavax, Takeda, Medicago, MedImmune, TechnoVax, Agilvax, Allergy Therapeutics, Serum Institute of India, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Virus Like Particles, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Virus Like Particles.
The Virus Like Particles market size, estimations, and forecasts are provided in terms of sales volume (K Dose) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Virus Like Particles market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Virus Like Particles manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Virus Like Particles Market Report

Report Metric Details
Report Name Virus Like Particles Market
Segment by Type
  • Adeno-Associated Virus
  • HIV
  • Hepatitis B Virus
  • Hepatitis C Virus
  • Others
Segment by Application
  • Vaccines
  • Mycoviruses
  • Virus Research
  • Therapeutic and Imaging Agents
  • Others
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company GlaxoSmithKline, Merck, Novavax, Takeda, Medicago, MedImmune, TechnoVax, Agilvax, Allergy Therapeutics, Serum Institute of India, GeoVax Labs, Cytos Biotechnology, ANGANY Genetics, CPL Biologicals, Xiamen Innovax Biotech
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Virus Like Particles manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Virus Like Particles in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the Virus Like Particles Market report?

Ans: The main players in the Virus Like Particles Market are GlaxoSmithKline, Merck, Novavax, Takeda, Medicago, MedImmune, TechnoVax, Agilvax, Allergy Therapeutics, Serum Institute of India, GeoVax Labs, Cytos Biotechnology, ANGANY Genetics, CPL Biologicals, Xiamen Innovax Biotech

What are the Application segmentation covered in the Virus Like Particles Market report?

Ans: The Applications covered in the Virus Like Particles Market report are Vaccines, Mycoviruses, Virus Research, Therapeutic and Imaging Agents, Others

What are the Type segmentation covered in the Virus Like Particles Market report?

Ans: The Types covered in the Virus Like Particles Market report are Adeno-Associated Virus, HIV, Hepatitis B Virus, Hepatitis C Virus, Others

1 Virus Like Particles Market Overview
1.1 Product Definition
1.2 Virus Like Particles by Type
1.2.1 Global Virus Like Particles Market Value Comparison by Type (2024 VS 2031)
1.2.2 Adeno-Associated Virus
1.2.3 HIV
1.2.4 Hepatitis B Virus
1.2.5 Hepatitis C Virus
1.2.6 Others
1.3 Virus Like Particles by Application
1.3.1 Global Virus Like Particles Market Value by Application (2024 VS 2031)
1.3.2 Vaccines
1.3.3 Mycoviruses
1.3.4 Virus Research
1.3.5 Therapeutic and Imaging Agents
1.3.6 Others
1.4 Global Virus Like Particles Market Size Estimates and Forecasts
1.4.1 Global Virus Like Particles Revenue 2020-2031
1.4.2 Global Virus Like Particles Sales 2020-2031
1.4.3 Global Virus Like Particles Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Virus Like Particles Market Competition by Manufacturers
2.1 Global Virus Like Particles Sales Market Share by Manufacturers (2020-2025)
2.2 Global Virus Like Particles Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Virus Like Particles Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Virus Like Particles, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Virus Like Particles, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Virus Like Particles, Product Type & Application
2.7 Global Key Manufacturers of Virus Like Particles, Date of Enter into This Industry
2.8 Global Virus Like Particles Market Competitive Situation and Trends
2.8.1 Global Virus Like Particles Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Virus Like Particles Players Market Share by Revenue
2.8.3 Global Virus Like Particles Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Virus Like Particles Market Scenario by Region
3.1 Global Virus Like Particles Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Virus Like Particles Sales by Region: 2020-2031
3.2.1 Global Virus Like Particles Sales by Region: 2020-2025
3.2.2 Global Virus Like Particles Sales by Region: 2026-2031
3.3 Global Virus Like Particles Revenue by Region: 2020-2031
3.3.1 Global Virus Like Particles Revenue by Region: 2020-2025
3.3.2 Global Virus Like Particles Revenue by Region: 2026-2031
3.4 North America Virus Like Particles Market Facts & Figures by Country
3.4.1 North America Virus Like Particles Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Virus Like Particles Sales by Country (2020-2031)
3.4.3 North America Virus Like Particles Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Virus Like Particles Market Facts & Figures by Country
3.5.1 Europe Virus Like Particles Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Virus Like Particles Sales by Country (2020-2031)
3.5.3 Europe Virus Like Particles Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Virus Like Particles Market Facts & Figures by Region
3.6.1 Asia Pacific Virus Like Particles Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Virus Like Particles Sales by Region (2020-2031)
3.6.3 Asia Pacific Virus Like Particles Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Virus Like Particles Market Facts & Figures by Country
3.7.1 Latin America Virus Like Particles Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Virus Like Particles Sales by Country (2020-2031)
3.7.3 Latin America Virus Like Particles Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Virus Like Particles Market Facts & Figures by Country
3.8.1 Middle East and Africa Virus Like Particles Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Virus Like Particles Sales by Country (2020-2031)
3.8.3 Middle East and Africa Virus Like Particles Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Virus Like Particles Sales by Type (2020-2031)
4.1.1 Global Virus Like Particles Sales by Type (2020-2025)
4.1.2 Global Virus Like Particles Sales by Type (2026-2031)
4.1.3 Global Virus Like Particles Sales Market Share by Type (2020-2031)
4.2 Global Virus Like Particles Revenue by Type (2020-2031)
4.2.1 Global Virus Like Particles Revenue by Type (2020-2025)
4.2.2 Global Virus Like Particles Revenue by Type (2026-2031)
4.2.3 Global Virus Like Particles Revenue Market Share by Type (2020-2031)
4.3 Global Virus Like Particles Price by Type (2020-2031)
5 Segment by Application
5.1 Global Virus Like Particles Sales by Application (2020-2031)
5.1.1 Global Virus Like Particles Sales by Application (2020-2025)
5.1.2 Global Virus Like Particles Sales by Application (2026-2031)
5.1.3 Global Virus Like Particles Sales Market Share by Application (2020-2031)
5.2 Global Virus Like Particles Revenue by Application (2020-2031)
5.2.1 Global Virus Like Particles Revenue by Application (2020-2025)
5.2.2 Global Virus Like Particles Revenue by Application (2026-2031)
5.2.3 Global Virus Like Particles Revenue Market Share by Application (2020-2031)
5.3 Global Virus Like Particles Price by Application (2020-2031)
6 Key Companies Profiled
6.1 GlaxoSmithKline
6.1.1 GlaxoSmithKline Company Information
6.1.2 GlaxoSmithKline Description and Business Overview
6.1.3 GlaxoSmithKline Virus Like Particles Sales, Revenue and Gross Margin (2020-2025)
6.1.4 GlaxoSmithKline Virus Like Particles Product Portfolio
6.1.5 GlaxoSmithKline Recent Developments/Updates
6.2 Merck
6.2.1 Merck Company Information
6.2.2 Merck Description and Business Overview
6.2.3 Merck Virus Like Particles Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Merck Virus Like Particles Product Portfolio
6.2.5 Merck Recent Developments/Updates
6.3 Novavax
6.3.1 Novavax Company Information
6.3.2 Novavax Description and Business Overview
6.3.3 Novavax Virus Like Particles Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Novavax Virus Like Particles Product Portfolio
6.3.5 Novavax Recent Developments/Updates
6.4 Takeda
6.4.1 Takeda Company Information
6.4.2 Takeda Description and Business Overview
6.4.3 Takeda Virus Like Particles Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Takeda Virus Like Particles Product Portfolio
6.4.5 Takeda Recent Developments/Updates
6.5 Medicago
6.5.1 Medicago Company Information
6.5.2 Medicago Description and Business Overview
6.5.3 Medicago Virus Like Particles Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Medicago Virus Like Particles Product Portfolio
6.5.5 Medicago Recent Developments/Updates
6.6 MedImmune
6.6.1 MedImmune Company Information
6.6.2 MedImmune Description and Business Overview
6.6.3 MedImmune Virus Like Particles Sales, Revenue and Gross Margin (2020-2025)
6.6.4 MedImmune Virus Like Particles Product Portfolio
6.6.5 MedImmune Recent Developments/Updates
6.7 TechnoVax
6.7.1 TechnoVax Company Information
6.7.2 TechnoVax Description and Business Overview
6.7.3 TechnoVax Virus Like Particles Sales, Revenue and Gross Margin (2020-2025)
6.7.4 TechnoVax Virus Like Particles Product Portfolio
6.7.5 TechnoVax Recent Developments/Updates
6.8 Agilvax
6.8.1 Agilvax Company Information
6.8.2 Agilvax Description and Business Overview
6.8.3 Agilvax Virus Like Particles Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Agilvax Virus Like Particles Product Portfolio
6.8.5 Agilvax Recent Developments/Updates
6.9 Allergy Therapeutics
6.9.1 Allergy Therapeutics Company Information
6.9.2 Allergy Therapeutics Description and Business Overview
6.9.3 Allergy Therapeutics Virus Like Particles Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Allergy Therapeutics Virus Like Particles Product Portfolio
6.9.5 Allergy Therapeutics Recent Developments/Updates
6.10 Serum Institute of India
6.10.1 Serum Institute of India Company Information
6.10.2 Serum Institute of India Description and Business Overview
6.10.3 Serum Institute of India Virus Like Particles Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Serum Institute of India Virus Like Particles Product Portfolio
6.10.5 Serum Institute of India Recent Developments/Updates
6.11 GeoVax Labs
6.11.1 GeoVax Labs Company Information
6.11.2 GeoVax Labs Description and Business Overview
6.11.3 GeoVax Labs Virus Like Particles Sales, Revenue and Gross Margin (2020-2025)
6.11.4 GeoVax Labs Virus Like Particles Product Portfolio
6.11.5 GeoVax Labs Recent Developments/Updates
6.12 Cytos Biotechnology
6.12.1 Cytos Biotechnology Company Information
6.12.2 Cytos Biotechnology Description and Business Overview
6.12.3 Cytos Biotechnology Virus Like Particles Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Cytos Biotechnology Virus Like Particles Product Portfolio
6.12.5 Cytos Biotechnology Recent Developments/Updates
6.13 ANGANY Genetics
6.13.1 ANGANY Genetics Company Information
6.13.2 ANGANY Genetics Description and Business Overview
6.13.3 ANGANY Genetics Virus Like Particles Sales, Revenue and Gross Margin (2020-2025)
6.13.4 ANGANY Genetics Virus Like Particles Product Portfolio
6.13.5 ANGANY Genetics Recent Developments/Updates
6.14 CPL Biologicals
6.14.1 CPL Biologicals Company Information
6.14.2 CPL Biologicals Description and Business Overview
6.14.3 CPL Biologicals Virus Like Particles Sales, Revenue and Gross Margin (2020-2025)
6.14.4 CPL Biologicals Virus Like Particles Product Portfolio
6.14.5 CPL Biologicals Recent Developments/Updates
6.15 Xiamen Innovax Biotech
6.15.1 Xiamen Innovax Biotech Company Information
6.15.2 Xiamen Innovax Biotech Description and Business Overview
6.15.3 Xiamen Innovax Biotech Virus Like Particles Sales, Revenue and Gross Margin (2020-2025)
6.15.4 Xiamen Innovax Biotech Virus Like Particles Product Portfolio
6.15.5 Xiamen Innovax Biotech Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Virus Like Particles Industry Chain Analysis
7.2 Virus Like Particles Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Virus Like Particles Production Mode & Process Analysis
7.4 Virus Like Particles Sales and Marketing
7.4.1 Virus Like Particles Sales Channels
7.4.2 Virus Like Particles Distributors
7.5 Virus Like Particles Customer Analysis
8 Virus Like Particles Market Dynamics
8.1 Virus Like Particles Industry Trends
8.2 Virus Like Particles Market Drivers
8.3 Virus Like Particles Market Challenges
8.4 Virus Like Particles Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
GlaxoSmithKline PLC
Merck
Novavax Inc
Takeda
Medicago
MedImmune
TechnoVax
Agilvax
Allergy Therapeutics
Serum Institute of India
GeoVax Labs
Cytos Biotechnology
ANGANY Genetics
CPL Biologicals
Xiamen Innovax Biotech
List of Tables
 Table 1. Global Virus Like Particles Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Virus Like Particles Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Virus Like Particles Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Virus Like Particles Sales (K Dose) of Key Manufacturers (2020-2025)
 Table 5. Global Virus Like Particles Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Virus Like Particles Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Virus Like Particles Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Virus Like Particles Average Price (USD/Dose) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Virus Like Particles, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Virus Like Particles, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Virus Like Particles, Product Type & Application
 Table 12. Global Key Manufacturers of Virus Like Particles, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Virus Like Particles by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Virus Like Particles as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Virus Like Particles Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Virus Like Particles Sales by Region (2020-2025) & (K Dose)
 Table 18. Global Virus Like Particles Sales Market Share by Region (2020-2025)
 Table 19. Global Virus Like Particles Sales by Region (2026-2031) & (K Dose)
 Table 20. Global Virus Like Particles Sales Market Share by Region (2026-2031)
 Table 21. Global Virus Like Particles Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Virus Like Particles Revenue Market Share by Region (2020-2025)
 Table 23. Global Virus Like Particles Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Virus Like Particles Revenue Market Share by Region (2026-2031)
 Table 25. North America Virus Like Particles Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Virus Like Particles Sales by Country (2020-2025) & (K Dose)
 Table 27. North America Virus Like Particles Sales by Country (2026-2031) & (K Dose)
 Table 28. North America Virus Like Particles Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Virus Like Particles Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Virus Like Particles Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Virus Like Particles Sales by Country (2020-2025) & (K Dose)
 Table 32. Europe Virus Like Particles Sales by Country (2026-2031) & (K Dose)
 Table 33. Europe Virus Like Particles Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Virus Like Particles Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Virus Like Particles Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Virus Like Particles Sales by Region (2020-2025) & (K Dose)
 Table 37. Asia Pacific Virus Like Particles Sales by Region (2026-2031) & (K Dose)
 Table 38. Asia Pacific Virus Like Particles Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Virus Like Particles Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Virus Like Particles Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Virus Like Particles Sales by Country (2020-2025) & (K Dose)
 Table 42. Latin America Virus Like Particles Sales by Country (2026-2031) & (K Dose)
 Table 43. Latin America Virus Like Particles Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Virus Like Particles Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Virus Like Particles Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Virus Like Particles Sales by Country (2020-2025) & (K Dose)
 Table 47. Middle East and Africa Virus Like Particles Sales by Country (2026-2031) & (K Dose)
 Table 48. Middle East and Africa Virus Like Particles Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Virus Like Particles Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Virus Like Particles Sales (K Dose) by Type (2020-2025)
 Table 51. Global Virus Like Particles Sales (K Dose) by Type (2026-2031)
 Table 52. Global Virus Like Particles Sales Market Share by Type (2020-2025)
 Table 53. Global Virus Like Particles Sales Market Share by Type (2026-2031)
 Table 54. Global Virus Like Particles Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Virus Like Particles Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Virus Like Particles Revenue Market Share by Type (2020-2025)
 Table 57. Global Virus Like Particles Revenue Market Share by Type (2026-2031)
 Table 58. Global Virus Like Particles Price (USD/Dose) by Type (2020-2025)
 Table 59. Global Virus Like Particles Price (USD/Dose) by Type (2026-2031)
 Table 60. Global Virus Like Particles Sales (K Dose) by Application (2020-2025)
 Table 61. Global Virus Like Particles Sales (K Dose) by Application (2026-2031)
 Table 62. Global Virus Like Particles Sales Market Share by Application (2020-2025)
 Table 63. Global Virus Like Particles Sales Market Share by Application (2026-2031)
 Table 64. Global Virus Like Particles Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Virus Like Particles Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Virus Like Particles Revenue Market Share by Application (2020-2025)
 Table 67. Global Virus Like Particles Revenue Market Share by Application (2026-2031)
 Table 68. Global Virus Like Particles Price (USD/Dose) by Application (2020-2025)
 Table 69. Global Virus Like Particles Price (USD/Dose) by Application (2026-2031)
 Table 70. GlaxoSmithKline Company Information
 Table 71. GlaxoSmithKline Description and Business Overview
 Table 72. GlaxoSmithKline Virus Like Particles Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
 Table 73. GlaxoSmithKline Virus Like Particles Product
 Table 74. GlaxoSmithKline Recent Developments/Updates
 Table 75. Merck Company Information
 Table 76. Merck Description and Business Overview
 Table 77. Merck Virus Like Particles Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
 Table 78. Merck Virus Like Particles Product
 Table 79. Merck Recent Developments/Updates
 Table 80. Novavax Company Information
 Table 81. Novavax Description and Business Overview
 Table 82. Novavax Virus Like Particles Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
 Table 83. Novavax Virus Like Particles Product
 Table 84. Novavax Recent Developments/Updates
 Table 85. Takeda Company Information
 Table 86. Takeda Description and Business Overview
 Table 87. Takeda Virus Like Particles Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
 Table 88. Takeda Virus Like Particles Product
 Table 89. Takeda Recent Developments/Updates
 Table 90. Medicago Company Information
 Table 91. Medicago Description and Business Overview
 Table 92. Medicago Virus Like Particles Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
 Table 93. Medicago Virus Like Particles Product
 Table 94. Medicago Recent Developments/Updates
 Table 95. MedImmune Company Information
 Table 96. MedImmune Description and Business Overview
 Table 97. MedImmune Virus Like Particles Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
 Table 98. MedImmune Virus Like Particles Product
 Table 99. MedImmune Recent Developments/Updates
 Table 100. TechnoVax Company Information
 Table 101. TechnoVax Description and Business Overview
 Table 102. TechnoVax Virus Like Particles Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
 Table 103. TechnoVax Virus Like Particles Product
 Table 104. TechnoVax Recent Developments/Updates
 Table 105. Agilvax Company Information
 Table 106. Agilvax Description and Business Overview
 Table 107. Agilvax Virus Like Particles Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
 Table 108. Agilvax Virus Like Particles Product
 Table 109. Agilvax Recent Developments/Updates
 Table 110. Allergy Therapeutics Company Information
 Table 111. Allergy Therapeutics Description and Business Overview
 Table 112. Allergy Therapeutics Virus Like Particles Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
 Table 113. Allergy Therapeutics Virus Like Particles Product
 Table 114. Allergy Therapeutics Recent Developments/Updates
 Table 115. Serum Institute of India Company Information
 Table 116. Serum Institute of India Description and Business Overview
 Table 117. Serum Institute of India Virus Like Particles Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
 Table 118. Serum Institute of India Virus Like Particles Product
 Table 119. Serum Institute of India Recent Developments/Updates
 Table 120. GeoVax Labs Company Information
 Table 121. GeoVax Labs Description and Business Overview
 Table 122. GeoVax Labs Virus Like Particles Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
 Table 123. GeoVax Labs Virus Like Particles Product
 Table 124. GeoVax Labs Recent Developments/Updates
 Table 125. Cytos Biotechnology Company Information
 Table 126. Cytos Biotechnology Description and Business Overview
 Table 127. Cytos Biotechnology Virus Like Particles Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
 Table 128. Cytos Biotechnology Virus Like Particles Product
 Table 129. Cytos Biotechnology Recent Developments/Updates
 Table 130. ANGANY Genetics Company Information
 Table 131. ANGANY Genetics Description and Business Overview
 Table 132. ANGANY Genetics Virus Like Particles Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
 Table 133. ANGANY Genetics Virus Like Particles Product
 Table 134. ANGANY Genetics Recent Developments/Updates
 Table 135. CPL Biologicals Company Information
 Table 136. CPL Biologicals Description and Business Overview
 Table 137. CPL Biologicals Virus Like Particles Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
 Table 138. CPL Biologicals Virus Like Particles Product
 Table 139. CPL Biologicals Recent Developments/Updates
 Table 140. Xiamen Innovax Biotech Company Information
 Table 141. Xiamen Innovax Biotech Description and Business Overview
 Table 142. Xiamen Innovax Biotech Virus Like Particles Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
 Table 143. Xiamen Innovax Biotech Virus Like Particles Product
 Table 144. Xiamen Innovax Biotech Recent Developments/Updates
 Table 145. Key Raw Materials Lists
 Table 146. Raw Materials Key Suppliers Lists
 Table 147. Virus Like Particles Distributors List
 Table 148. Virus Like Particles Customers List
 Table 149. Virus Like Particles Market Trends
 Table 150. Virus Like Particles Market Drivers
 Table 151. Virus Like Particles Market Challenges
 Table 152. Virus Like Particles Market Restraints
 Table 153. Research Programs/Design for This Report
 Table 154. Key Data Information from Secondary Sources
 Table 155. Key Data Information from Primary Sources
 Table 156. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Virus Like Particles
 Figure 2. Global Virus Like Particles Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Virus Like Particles Market Share by Type: 2024 & 2031
 Figure 4. Adeno-Associated Virus Product Picture
 Figure 5. HIV Product Picture
 Figure 6. Hepatitis B Virus Product Picture
 Figure 7. Hepatitis C Virus Product Picture
 Figure 8. Others Product Picture
 Figure 9. Global Virus Like Particles Market Value by Application (2020-2031) & (US$ Million)
 Figure 10. Global Virus Like Particles Market Share by Application: 2024 & 2031
 Figure 11. Vaccines
 Figure 12. Mycoviruses
 Figure 13. Virus Research
 Figure 14. Therapeutic and Imaging Agents
 Figure 15. Others
 Figure 16. Global Virus Like Particles Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 17. Global Virus Like Particles Market Size (2020-2031) & (US$ Million)
 Figure 18. Global Virus Like Particles Sales (2020-2031) & (K Dose)
 Figure 19. Global Virus Like Particles Average Price (USD/Dose) & (2020-2031)
 Figure 20. Virus Like Particles Report Years Considered
 Figure 21. Virus Like Particles Sales Share by Manufacturers in 2024
 Figure 22. Global Virus Like Particles Revenue Share by Manufacturers in 2024
 Figure 23. Global 5 and 10 Largest Virus Like Particles Players: Market Share by Revenue in Virus Like Particles in 2024
 Figure 24. Virus Like Particles Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 25. Global Virus Like Particles Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 26. North America Virus Like Particles Sales Market Share by Country (2020-2031)
 Figure 27. North America Virus Like Particles Revenue Market Share by Country (2020-2031)
 Figure 28. U.S. Virus Like Particles Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. Canada Virus Like Particles Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. Europe Virus Like Particles Sales Market Share by Country (2020-2031)
 Figure 31. Europe Virus Like Particles Revenue Market Share by Country (2020-2031)
 Figure 32. Germany Virus Like Particles Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. France Virus Like Particles Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. U.K. Virus Like Particles Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. Italy Virus Like Particles Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. Russia Virus Like Particles Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. Asia Pacific Virus Like Particles Sales Market Share by Region (2020-2031)
 Figure 38. Asia Pacific Virus Like Particles Revenue Market Share by Region (2020-2031)
 Figure 39. China Virus Like Particles Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Japan Virus Like Particles Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. South Korea Virus Like Particles Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. India Virus Like Particles Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Australia Virus Like Particles Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Taiwan Virus Like Particles Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Indonesia Virus Like Particles Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Thailand Virus Like Particles Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Malaysia Virus Like Particles Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Philippines Virus Like Particles Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. Latin America Virus Like Particles Sales Market Share by Country (2020-2031)
 Figure 50. Latin America Virus Like Particles Revenue Market Share by Country (2020-2031)
 Figure 51. Mexico Virus Like Particles Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. Brazil Virus Like Particles Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. Argentina Virus Like Particles Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 54. Middle East and Africa Virus Like Particles Sales Market Share by Country (2020-2031)
 Figure 55. Middle East and Africa Virus Like Particles Revenue Market Share by Country (2020-2031)
 Figure 56. Turkey Virus Like Particles Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 57. Saudi Arabia Virus Like Particles Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 58. U.A.E Virus Like Particles Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 59. Global Sales Market Share of Virus Like Particles by Type (2020-2031)
 Figure 60. Global Revenue Market Share of Virus Like Particles by Type (2020-2031)
 Figure 61. Global Virus Like Particles Price (USD/Dose) by Type (2020-2031)
 Figure 62. Global Sales Market Share of Virus Like Particles by Application (2020-2031)
 Figure 63. Global Revenue Market Share of Virus Like Particles by Application (2020-2031)
 Figure 64. Global Virus Like Particles Price (USD/Dose) by Application (2020-2031)
 Figure 65. Virus Like Particles Value Chain
 Figure 66. Channels of Distribution (Direct Vs Distribution)
 Figure 67. Bottom-up and Top-down Approaches for This Report
 Figure 68. Data Triangulation
 Figure 69. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Nano Dimension

SIMILAR REPORTS

Global Virus like Particle VLP Vaccines Market Research Report 2024
Global Virus Filters Market Research Report 2024
Global Virus like Particles VLPs Delivery System Market Research Report 2024
Global Viral Vectors Market Research Report 2024
Global Viral Detection Market Research Report 2025
Global Particle Analyzers Market Research Report 2024
Global Virus Preservation Solution Market Research Report 2024
Global Virus Transport Medium Market Research Report 2024
Global Viral Vector Based Gene Therapy Market Research Report 2025
Global Particle Measuring Devices Market Research Report 2024
Global Particle Deposition Systems Market Research Report 2025
Global Anti virus Film Market Research Report 2025
Global Particle Building Block Market Research Report 2024
Global Particle Sensor Market Research Report 2025
Global Paper like Film Market Research Report 2025
Global Light Diffusion Particles Market Research Report 2024
Global Particle Beam Weapons Market Research Report 2024
Global Virus Test Kits Market Research Report 2024
Global Anti Virus Coating Market Research Report 2025
Global Poultry Viral Disease Vaccines Market Research Report 2024

RELATED REPORTS

Global GLP-1 Targeted Peptide Weight Loss Drugs Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-19A18322
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Stimulant-Free Fat Burners Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-3E3525
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Test Boosters Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-35T3049
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Salsalate Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-33Y1801
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions